In most cases of cardiotoxicity from HER2-targeted therapies, a decline in heart function will be found during routine monitoring with the patient having no symptoms or vague symptoms, such as fatigue. In some cases, however, the decrease in heart function will be accompanied by symptoms of heart failure.
In heart failure, the heart isn’t pumping as well as it should, which leads to fluid buildup in the lungs and eventually in the legs. Patients may experience:
If you develop any of these symptoms, talk to your doctor at once.
Learn how to make the most of trusted heart health information, incentive programs, health tracking tools and mobile resources available at CardioSmart.org.